Skip to content

Effectivity of 1 Finger Tip Unit Compared to 2 Finger Tip Units 0.05% Tretinoin Cream

Effectivity of 1 Finger Tip Unit Compared to 2 Finger Tip Units 0.05% Tretinoin Cream Before and After 30% Trichloroacetic Acid Chemical Peeling on Aging Skin

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05004909
Enrollment
46
Registered
2021-08-13
Start date
2021-09-01
Completion date
2022-01-31
Last updated
2021-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Photoaging

Keywords

Photoaging, Tretinoin, Trichloroacetic Acid, Chemical Peeling

Brief summary

This clinical study will compare the efficacy of using one fingertip unit and two fingertip units of 0.05% before and after 30% trichloroacetic acid chemical peel procedure for facial skin rejuvenation in 35-60 years old female patients with Glogau II-III skin classification.

Detailed description

This study is an experimental study with a randomized controlled trial (RCT) design on patients who met the inclusion criteria. Group A will receive pretreatment in the form of 0.05% tretinoin cream which is used as much as one fingertip unit every night, and group B will receive the same cream which should be used as much as two fingertip units. This cream will be used for two weeks before the patients receive a chemical peeling therapy using 30% trichloroacetic acid. The results of therapy will mainly be assessed based on the Dermoscopic Photoaging Scale (DPAS), as well as visual analog scale (VAS) for subjective symptoms and Clinician Erythema Assessment Scale (CEA) for erythema.

Interventions

DRUG0.05% Tretinoin

Topical 0.05% tretinoin cream applied daily every night by the subjects according to assigned randomization

Sponsors

Dr.dr.Irma Bernadette, SpKK (K)
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
35 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Female patients aged 35-60 years old * Patients with Glogau II-III skin classification * Patients are willing to participate in the study and sign an informed consent form

Exclusion criteria

* Patients with hypertrophic scars or keloid on the face * Patients with open wound or infection on the face * History of other topical treatment on the face within 1 month of enrollment * Pregnant or breastfeeding mother * Patients and/or their families are not willing to participate in the study.

Design outcomes

Primary

MeasureTime frameDescription
Change of Photoaged Skin ConditionBaseline(pre-chemical peeling procedure), immediately after chemical peeling procedure, and 4 weeks after chemical peeling procedureusing dermoscopic photoaging scale (DPAS). This DPAS assessment is based on yes or no rules on 11 criteria in four facial regions, namely left malar, right malar, forehead, and chin. The criteria were yellowish discoloration, white line, lentigo, hypo- and hyper-pigmented macules, telangiectasia, yellow papules, actinic keratosis, senile comedones, deep wrinkle, superficial wrinkle, and criss-cross wrinkle. Score range is 0-44 points.
Change of Subjective Pain EvaluationBaseline(pre-chemical peeling procedure), immediately after chemical peeling procedure, and 4 weeks after chemical peeling procedureusing Visual Analog Scale (VAS). Scale range is 0-10, 0 indicates no pain and 10 indicates severe pain
Change of Erythema DegreeBaseline(pre-chemical peeling procedure), immediately after chemical peeling procedure, and 4 weeks after chemical peeling procedureusing Clinician Erythema Assessment Scale (CEA). Scale range is 0-4, 0 indicates no erythema and 4 indicates severe erythema
Change in Skin ThicknessBaseline(pre-chemical peeling procedure) and 4 weeks after chemical peeling procedureEvaluation with USG of epidermal and dermal layer (in pixels)

Countries

Indonesia

Contacts

Primary ContactIrma BS Sitohang, MD
irma_bernadette@yahoo.com+62818130761

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026